期刊
MOLECULAR THERAPY
卷 25, 期 9, 页码 2140-2149出版社
CELL PRESS
DOI: 10.1016/j.ymthe.2017.05.018
关键词
-
资金
- National Natural Science Foundation of China [81402216, 81672657]
- Beijing New-star Plan of Science and Technology [Z14110700181409]
- Natural Science Foundation of Chongqing Science and Technology Commission [cstc2313jcyjA10106]
- Startup Fund for Talented Scholars of Daping Hospital and Research Institute of Surgery, Third Military Medical University
Dysregulated microRNAs (miRNAs) play an important role in osteosarcoma (OS) progression. In the present study, we investigate the clinical significance of serum miR-491 level and the potential role of miR-491 in OS lung metastasis and chemoresistance. Clinical data show that the level of miR-491 was decreased in serum from OS patients compared with healthy control subjects, and that a decreased serum miR-491 level is correlated with increased metastasis, poor chemoresponse, and lower survival rate in OS patients. In vitro and in vivo experiments show that overexpression of miR-491 suppresses OS cell lung metastasis, whereas it enhances cisplatin (CDDP)induced tumor growth inhibition and apoptosis. In contrast, inhibition of miR-491 stimulates OS cell lung metastasis and suppresses CDDP-induced tumor growth inhibition and apoptosis. Furthermore, we demonstrate that miR-491 exerts its role by directly targeting alpha B-crystallin (CRYAB) in OS. Our findings suggest that serum level of miR-491 has potential as a biomarker for predicting OS progression and prognosis of OS patients. Additionally, restoration of miR-491 may be a novel strategy for inhibiting OS lung metastasis and overcoming OS cell resistance to chemotherapy.
作者
我是这篇论文的作者
点击您的名字以认领此论文并将其添加到您的个人资料中。
推荐
暂无数据